The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) study
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Fenofibrate (Primary) ; Metformin
- Indications Hypertriglyceridaemia; Insulin resistance; Metabolic syndrome
- Focus Therapeutic Use
- Acronyms FAMA
- 31 Aug 2018 Biomarkers information updated
- 15 Aug 2016 Status changed from active, no longer recruiting to completed.
- 06 Dec 2007 The expected completion date for this trial is now 1 Nov 2008.